Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01144260
Recruitment Status : Completed
First Posted : June 15, 2010
Last Update Posted : May 15, 2013
Information provided by (Responsible Party):

Brief Summary:
A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Condition or disease Intervention/treatment Phase
B-Cell Chronic Lymphocytic Leukemia Drug: bafetinib Phase 2

Detailed Description:
Bafetinib is a dual protein kinase inhibitor, targeting both bcr/abl and Lyn kinases. B-cell chronic lymphocytic leukemia cells overexpress Lyn kinase compared to normal B lymphocytes as well as acute leukemias (ALL and AML), and inhibition of Lyn kinase induces apoptosis in cultures of B-CLL cells. Thus, bafetinib may stop the growth of B-CLL cells by inhibiting Lyn kinase, the molecule that couples the B cell receptor to downstream signaling.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Study Start Date : June 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Bafetinib Drug: bafetinib
250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
Other Name: INNO-406

Primary Outcome Measures :
  1. To evaluate the response rate (complete and partial), in subjects with relapsed or refractory B-Cell CLL [ Time Frame: Upto 6 months or disease progression ]

Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥18 years, male or female.
  • B-cell chronic lymphocytic leukemia meeting the WHO criteria.
  • Relapsed or refractory disease with at least one of the following criteria: *progression after at least one course of a purine nucleoside analog (fludarabine phosphate, cladribine, pentostatin)

    • progression after at least one course of an alkylating agent (cyclophosphamide or chlorambucil)
    • relapse within 12 months after at least one course of either a purine nucleoside or an alkylating agent.
  • Capable of providing informed consent and complying with trial procedures.
  • ECOG performance status 0-2.
  • Requires chemotherapy for disease as shown by any of the following criteria:

    • measurable and progressive lymphocytosis
    • measurable and progressive lymphadenopathy (lymph node ≥2 cm in a single diameter)
    • either weight loss ≥10% within the past 6 months or extreme fatigue due to leukemia
    • fevers ≥100.5 degrees F for 2 weeks with no source of infection
    • night sweats with no evidence of infection
    • progressive marrow failure (worsening anemia with hemoglobin <10 gm/dL and/or thrombocytopenia with platelet count <100,000/mm3)
    • massive or progressive splenomegaly (spleen >6 cm below left costal margin).
  • Women must not be able to become pregnant (e.g. post menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. [Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.]
  • Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
  • Accessibility to the site.

Exclusion Criteria:

  • Chemotherapy, antibody therapy, surgery within 4 weeks of study enrollment.
  • Exposure to any investigational agent within 30 days of the Screening Visit.
  • Known CNS disease.
  • Concurrent active malignancies except basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix.
  • Laboratory values: Screening creatinine clearance (calculated by Cockcroft Gault formula) of less than 50 mL/minute, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal, total bilirubin greater than 3 times the upper limit of normal, white blood cell (WBC) count <3500/mm3, absolute neutrophil count <1000/mm3, hematocrit level <33% for females or <35% for males.
  • Clinically evident congestive heart failure >class II of the New York Heart Association (NYHA) guidelines.
  • Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
  • History or signs of active coronary artery disease with or without angina pectoris.
  • Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) <45% of predicted.
  • Known HIV infection.
  • Uncontrolled active, infection.
  • Major surgery within 3 weeks prior to treatment.
  • Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
  • Any condition that in the opinion of the Investigator is unstable and could jeopardize the subject's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01144260

Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
United States, Texas
UT M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Layout table for investigator information
Study Director: Daniel Levitt, M.D., Ph.D. CytRx
Layout table for additonal information
Responsible Party: CytRx Identifier: NCT01144260    
Other Study ID Numbers: BAFETINIB-P2-CLL-01
First Posted: June 15, 2010    Key Record Dates
Last Update Posted: May 15, 2013
Last Verified: May 2013
Keywords provided by CytRx:
chronic lymphocytic leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action